Overview: Helicobacter Pylori IgM TestIntroduction: The Helicobacter Pylori IgM Test detects IgM antibodies to Helicobacter pylori to diagnose recent infections, causing stomach pain or ulcers. Aligned with 2023 ACG guidelines, it uses an immunoassay for high sensitivity, aiding in infectious disease screening. This test is critical for guiding diagnosis, antibiotic treatment, and improving outcomes in serology for patients with suspected H. pylori infections, which are linked to gastritis and peptic ulcers.
Other Names: H. Pylori IgM Assay, Anti-H. Pylori IgM Test.
FDA Status: Laboratory-developed test (LDT), meeting serology standards for diagnostic accuracy.
Historical Milestone: H. pylori antibody testing began in the 1980s after its discovery as a cause of ulcers. IgM immunoassays were refined in the 1990s for acute infection detection.
Purpose: Diagnoses recent H. pylori infection, guides antibiotic therapy, and monitors IgM antibody levels in patients with stomach pain or ulcers.
Test Parameters: 1. Helicobacter Pylori IgM
Pretest Condition: No fasting required. Collect serum or saliva at any time. Report symptoms like stomach pain, nausea, or ulcers, and list medications, especially antibiotics or PPIs.
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document stomach pain, ulcers, dyspepsia, or history of H. pylori infection. Include current medications, especially antibiotics or proton pump inhibitors, and recent treatments.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for antibiotic therapy or follow-up testing.
Procedural Considerations: Uses an immunoassay to detect H. pylori IgM antibodies. Results are available in 1-2 days, enabling rapid clinical decisions. Performed in laboratories, often as part of dyspepsia evaluation protocols.
Factors Affecting Result Accuracy: Recent antibiotic or PPI use, improper sample handling, or early infection can affect results. Cross-reactivity with other infections may occur.
Clinical Significance: Positive IgM indicates recent H. pylori infection, prompting antibiotic therapy (e.g., clarithromycin-based regimens). Negative results may require further testing to confirm.
Specialist Consultation: Consult a gastroenterologist for result interpretation and treatment planning.
Additional Supporting Tests: H. pylori IgG, urea breath test, stool antigen test, or endoscopy to confirm infection and assess severity.
Test Limitations: IgM may be negative in early or chronic infections. False positives can occur due to cross-reactivity. Clinical correlation is essential.
References: ACG H. Pylori Guidelines, 2023; Gastroenterology, Chey WD, 2022.
